J Law Med Ethics. 2022;50(S1):24-28. doi: 10.1017/jme.2022.31.
The efficacy of pre-exposure prophylaxis, PrEP, with antiviral agents for prevention of HIV infection has been demonstrated in multiple randomized controlled trials and demonstration projects. These trials have studied prevention at the individual level. The effectiveness of PrEP as a public health intervention to reduce HIV incidence at community and population levels is being actively evaluated but is less well described. In reviewing the available data on PrEP as a public health intervention, three significant examples have demonstrated success, and all have been among communities of gay, bisexual and other men who have sex with men (MSM).
抗病毒药物的暴露前预防（PrEP）在多项随机对照试验和示范项目中被证明可有效预防 HIV 感染。这些试验研究了个体层面的预防。PrEP 作为一项公共卫生干预措施，在减少社区和人群 HIV 发病率方面的有效性正在积极评估，但描述得还不够充分。在审查 PrEP 作为公共卫生干预措施的现有数据时，有三个显著的例子表明其取得了成功，而且都发生在男同性恋、双性恋和其他男男性行为者（MSM）群体中。
